Your browser doesn't support javascript.
loading
Daily allergic multimorbidity in rhinitis using mobile technology: A novel concept of the MASK study.
Bousquet, J; Devillier, P; Anto, J M; Bewick, M; Haahtela, T; Arnavielhe, S; Bedbrook, A; Murray, R; van Eerd, M; Fonseca, J A; Morais Almeida, M; Todo Bom, A; Menditto, E; Passalacqua, G; Stellato, C; Triggiani, M; Ventura, M T; Vezzani, G; Annesi-Maesano, I; Bourret, R; Bosse, I; Caimmi, D; Cartier, C; Demoly, P; Just, J; Portejoie, F; Siroux, V; Viart, F; Bergmann, K C; Keil, T; Klimek, L; Mösges, R; Pfaar, O; Shamai, S; Zuberbier, T; Mullol, J; Valero, A; Spranger, O; Tomazic, P V; Kowalski, M L; Kuna, P; Kupczyk, M; Raciborski, F; Samolinski, B; Toppila-Salmi, S K; Valovirta, E; Cruz, A A; Sarquis-Serpa, F; da Silva, J; Stelmach, R.
Afiliación
  • Bousquet J; MACVIA-France, Contre les MAladies Chroniques pour un VIeillissement Actif en France European Innovation Partnership on Active and Healthy Ageing Reference Site, Montpellier, France.
  • Devillier P; INSERM U 1168, VIMA: Ageing and Chronic Diseases Epidemiological and Public Health Approaches, Villejuif, France.
  • Anto JM; UMR-S 1168, Université Versailles St-Quentin-en-Yvelines, Montigny le Bretonneux, France.
  • Bewick M; Euforea, Brussels, Belgium.
  • Haahtela T; Charité, Berlin, Germany.
  • Arnavielhe S; Laboratoire de Pharmacologie Respiratoire UPRES EA220, Pôle des Maladies Respiratoires, Hôpital Foch, Suresnes Université Versailles Saint-Quentin, Suresnes, France.
  • Bedbrook A; ISGloBAL, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain.
  • Murray R; IMIM (Hospital del Mar Research Institute), Barcelona, Spain.
  • van Eerd M; CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.
  • Fonseca JA; Universitat Pompeu Fabra (UPF), Barcelona, Spain.
  • Morais Almeida M; iQ4U Consultants Ltd, London, UK.
  • Todo Bom A; Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland.
  • Menditto E; Kyomed, Montpellier, France.
  • Passalacqua G; MACVIA-France, Contre les MAladies Chroniques pour un VIeillissement Actif en France European Innovation Partnership on Active and Healthy Ageing Reference Site, Montpellier, France.
  • Stellato C; MedScript Ltd, Dundalk, Ireland.
  • Triggiani M; Peercode DV, Gerdermalsen, The Netherlands.
  • Ventura MT; Faculdade de Medicina, Center for Health Technology and Services Research- CINTESIS, MEDIDA, Lda, Universidade do Porto, Porto, Portugal.
  • Vezzani G; Allergy and Clinical Immunology Department, Hospital CUF-Descobertas, Lisboa, Portugal.
  • Annesi-Maesano I; Imunoalergologia, Faculty of Medicine, Centro Hospitalar Universitário de Coimbra, University of Coimbra, Coimbra, Portugal.
  • Bourret R; CIRFF, Center of Pharmacoeconomics, University of Naples Federico II, Naples, Italy.
  • Bosse I; Allergy and Respiratory Diseases, Ospedale Policlinico San Martino, University of Genoa, Genoa, Italy.
  • Caimmi D; Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Salerno, Italy.
  • Cartier C; Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Salerno, Italy.
  • Demoly P; Unit of Geriatric Immunoallergology, University of Bari Medical School, Bari, Italy.
  • Just J; Pulmonary Unit, Department of Medical Specialties, Arcispedale SMaria Nuova/IRCCS, AUSL di Reggio Emilia, Reggio Emilia, Italy.
  • Portejoie F; Epidemiology of Allergic and Respiratory Diseases, Department Institute Pierre Louis of Epidemiology and Public Health, INSERM, Medical School Saint Antoine, UPMC Sorbonne Universités, Paris, France.
  • Siroux V; Centre Hospitalier, Valenciennes, France.
  • Viart F; Allergist, La Rochelle, France.
  • Bergmann KC; CHRU de Montpellier, UMR-S 1136, IPLESP, Equipe EPAR, UPMC Paris 06, Sorbonne Universités, Paris, France.
  • Keil T; ASA - Advanced Solutions Accelerator, Clapiers, France.
  • Klimek L; CHRU de Montpellier, UMR-S 1136, IPLESP, Equipe EPAR, UPMC Paris 06, Sorbonne Universités, Paris, France.
  • Mösges R; Allergology Department, Centre de l'Asthme et des Allergies Hôpital d'Enfants Armand-Trousseau (APHP), Paris, France.
  • Pfaar O; UMR_S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Equipe EPAR, UPMC Univ Paris 06, Sorbonne Universités, Paris, France.
  • Shamai S; MACVIA-France, Contre les MAladies Chroniques pour un VIeillissement Actif en France European Innovation Partnership on Active and Healthy Ageing Reference Site, Montpellier, France.
  • Zuberbier T; INSERM, IAB, U 1209, Team of Environmental Epidemiology applied to Reproduction and Respiratory Health, Université Grenoble Alpes, Université Joseph Fourier, Grenoble, France.
  • Mullol J; ASA - Advanced Solutions Accelerator, Clapiers, France.
  • Valero A; Department of Dermatology and Allergy, Comprehensive Allergy-Centre-Charité, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Spranger O; Global Allergy and Asthma European Network (GA2LEN), Berlin, Germany.
  • Tomazic PV; Institute of Social Medicine, Epidemiology and Health Economics, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Kowalski ML; Institute for Clinical Epidemiology and Biometry, University of Wuerzburg, Wuerzburg, Germany.
  • Kuna P; Center for Rhinology and Allergology, Wiesbaden, Germany.
  • Kupczyk M; Department of Otorhinolaryngology, Head and Neck Surgery, Medical Faculty Mannheim, Universitätsmedizin Mannheim, Heidelberg University, Mannheim, Germany.
  • Raciborski F; CRI-Clinical Research International-Ltd, Hamburg, Germany.
  • Samolinski B; Center for Rhinology and Allergology, Wiesbaden, Germany.
  • Toppila-Salmi SK; Department of Otorhinolaryngology, Head and Neck Surgery, Medical Faculty Mannheim, Universitätsmedizin Mannheim, Heidelberg University, Mannheim, Germany.
  • Valovirta E; CRI-Clinical Research International-Ltd, Hamburg, Germany.
  • Cruz AA; Medical Faculty, Institute of Medical Statistics, and Computational Biology, University of Cologne, Cologne, Germany.
  • Sarquis-Serpa F; Department of Dermatology and Allergy, Comprehensive Allergy-Centre-Charité, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • da Silva J; Global Allergy and Asthma European Network (GA2LEN), Berlin, Germany.
  • Stelmach R; Rhinology Unit & Smell Clínic, ENT Department, Hospital Clinic, University of Barcelona, Barcelona, Spain.
Allergy ; 73(8): 1622-1631, 2018 08.
Article en En | MEDLINE | ID: mdl-29569295
ABSTRACT

BACKGROUND:

Multimorbidity in allergic airway diseases is well known, but no data exist about the daily dynamics of symptoms and their impact on work. To better understand this, we aimed to assess the presence and control of daily allergic multimorbidity (asthma, conjunctivitis, rhinitis) and its impact on work productivity using a mobile technology, the Allergy Diary.

METHODS:

We undertook a 1-year prospective observational study in which 4 210 users and 32 585 days were monitored in 19 countries. Five visual analogue scales (VAS) assessed the daily burden of the disease (i.e., global evaluation, nose, eyes, asthma and work). Visual analogue scale levels <20/100 were categorized as "Low" burden and VAS levels ≥50/100 as "High" burden.

RESULTS:

Visual analogue scales global measured levels assessing the global control of the allergic disease were significantly associated with allergic multimorbidity. Eight hypothesis-driven patterns were defined based on "Low" and "High" VAS levels. There were <0.2% days of Rhinitis Low and Asthma High or Conjunctivitis High patterns. There were 5.9% days with a Rhinitis High-Asthma Low pattern. There were 1.7% days with a Rhinitis High-Asthma High-Conjunctivitis Low pattern. A novel Rhinitis High-Asthma High-Conjunctivitis High pattern was identified in 2.9% days and had the greatest impact on uncontrolled VAS global measured and impaired work productivity. Work productivity was significantly correlated with VAS global measured levels.

CONCLUSIONS:

In a novel approach examining daily symptoms with mobile technology, we found considerable intra-individual variability of allergic multimorbidity including a previously unrecognized extreme pattern of uncontrolled multimorbidity.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Rinitis / Aplicaciones Móviles / Multimorbilidad / Hipersensibilidad Tipo de estudio: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Aged80 / Child / Female / Humans / Male / Middle aged Idioma: En Revista: Allergy Año: 2018 Tipo del documento: Article País de afiliación: Francia

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Rinitis / Aplicaciones Móviles / Multimorbilidad / Hipersensibilidad Tipo de estudio: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Aged80 / Child / Female / Humans / Male / Middle aged Idioma: En Revista: Allergy Año: 2018 Tipo del documento: Article País de afiliación: Francia